赛克莱里安与科萨纳合并,形成KRSA,获得3.8亿美元用于推进阿尔茨海默病药物. Cyclerion merges with Korsana to form KRSA, securing $380M to advance Alzheimer's drug.

在宣布与科萨纳生物科学公司合并后, 赛克莱里安股价升. Cyclerion shares surged after announcing an all-stock merger with Korsana Biosciences, creating a new company trading under the ticker KRSA. 这笔交易包括3.8亿美元的新资金, 由通用大西洋等投资者领导, 将公司的跑道延长到2029年. The deal includes $380 million in new funding, led by investors like General Atlantic, extending the company's runway into 2029. 合并后的实体将专注于KRSA-028,这是潜在的阿尔茨海默氏症治疗方法,预计到2027年底就会实现关键临床里程碑. The combined entity will focus on KRSA-028, a potential Alzheimer's treatment, with key clinical milestones expected by late 2027.